Inhaled Tranexamic Acid for the Management of Hemoptysis in a Patient With Right and Left Ventricular Assist Devices: A Case Report

Shamik Patel; Ioannis K. Angelidis; Elizabeth S. Malsin; Sean B Smith; Amit Audumbar Pawale; Ashley N. Budd

doi:10.1213/XAA.0000000000001604

Inhaled Tranexamic Acid for the Management of Hemoptysis in a Patient With Right and Left Ventricular Assist Devices: A Case Report

Shamik Patel, Ioannis K. Angelidis, Elizabeth S. Malsin, Sean B Smith, Amit Audumbar Pawale, Ashley N. Budd

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The use of mechanical circulatory support (MCS) devices continues to expand in cases of refractory cardiogenic shock. Bleeding is one of the most common complications associated with MCS, and management can be challenging due to need for systemic anticoagulation. Significant hemoptysis can be a devastating complication. We describe a case of a patient supported by a right ventricular assist device with an oxygenator and a left ventricular assist device who developed pulmonary hemorrhage that was successfully treated with nebulized tranexamic acid (TXA). Following a 5-day treatment course, bleeding resolved, no adverse side effects were noted, and systemic anticoagulation was resumed.

Original language	English (US)
Pages (from-to)	e01604
Journal	A&A practice
Volume	16
Issue number	8
DOIs	https://doi.org/10.1213/XAA.0000000000001604
State	Published - Aug 1 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1213/XAA.0000000000001604

Cite this

@article{3e28b9501d1e49428ad9279fad78eef2,

title = "Inhaled Tranexamic Acid for the Management of Hemoptysis in a Patient With Right and Left Ventricular Assist Devices: A Case Report",

abstract = "The use of mechanical circulatory support (MCS) devices continues to expand in cases of refractory cardiogenic shock. Bleeding is one of the most common complications associated with MCS, and management can be challenging due to need for systemic anticoagulation. Significant hemoptysis can be a devastating complication. We describe a case of a patient supported by a right ventricular assist device with an oxygenator and a left ventricular assist device who developed pulmonary hemorrhage that was successfully treated with nebulized tranexamic acid (TXA). Following a 5-day treatment course, bleeding resolved, no adverse side effects were noted, and systemic anticoagulation was resumed.",

author = "Shamik Patel and Angelidis, {Ioannis K.} and Malsin, {Elizabeth S.} and Smith, {Sean B} and Pawale, {Amit Audumbar} and Budd, {Ashley N.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 International Anesthesia Research Society.",

year = "2022",

month = aug,

day = "1",

doi = "10.1213/XAA.0000000000001604",

language = "English (US)",

volume = "16",

pages = "e01604",

journal = "A&A practice",

issn = "2325-7237",

publisher = "Wolters Kluwer Health",

number = "8",

}

TY - JOUR

T1 - Inhaled Tranexamic Acid for the Management of Hemoptysis in a Patient With Right and Left Ventricular Assist Devices

T2 - A Case Report

AU - Patel, Shamik

AU - Angelidis, Ioannis K.

AU - Malsin, Elizabeth S.

AU - Smith, Sean B

AU - Pawale, Amit Audumbar

AU - Budd, Ashley N.

PY - 2022/8/1

Y1 - 2022/8/1

N2 - The use of mechanical circulatory support (MCS) devices continues to expand in cases of refractory cardiogenic shock. Bleeding is one of the most common complications associated with MCS, and management can be challenging due to need for systemic anticoagulation. Significant hemoptysis can be a devastating complication. We describe a case of a patient supported by a right ventricular assist device with an oxygenator and a left ventricular assist device who developed pulmonary hemorrhage that was successfully treated with nebulized tranexamic acid (TXA). Following a 5-day treatment course, bleeding resolved, no adverse side effects were noted, and systemic anticoagulation was resumed.

AB - The use of mechanical circulatory support (MCS) devices continues to expand in cases of refractory cardiogenic shock. Bleeding is one of the most common complications associated with MCS, and management can be challenging due to need for systemic anticoagulation. Significant hemoptysis can be a devastating complication. We describe a case of a patient supported by a right ventricular assist device with an oxygenator and a left ventricular assist device who developed pulmonary hemorrhage that was successfully treated with nebulized tranexamic acid (TXA). Following a 5-day treatment course, bleeding resolved, no adverse side effects were noted, and systemic anticoagulation was resumed.

UR - http://www.scopus.com/inward/record.url?scp=85135597514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135597514&partnerID=8YFLogxK

U2 - 10.1213/XAA.0000000000001604

DO - 10.1213/XAA.0000000000001604

M3 - Article

C2 - 35917204

AN - SCOPUS:85135597514

SN - 2325-7237

VL - 16

SP - e01604

JO - A&A practice

JF - A&A practice

IS - 8

ER -

Inhaled Tranexamic Acid for the Management of Hemoptysis in a Patient With Right and Left Ventricular Assist Devices: A Case Report

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this